poisar

Stocks · News reference

Theralase Technologies Inc. Provides Bladder Cancer Clinical Study Update

Fiscal.ai

Theralase Technologies Inc. announced the completion of enrollment for its Phase II clinical study of its bladder cancer treatment and outlined plans for future regulatory submissions.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolSara Appino

    Which Long-Term Bond ETF Is the Better Buy: State Street’s SPLB or iShares’ TLT?

    The article compares two long-term bond ETFs: State Street's SPLB (corporate bonds) and iShares' TLT (Treasury bonds). SPLB offers a lower expense ratio (0.04% vs 0.15%), higher yield (6.3% vs 5.2%), and better 5-year performance with smaller drawdowns. TLT provides safer government-backed securities with higher liquidity. For most long-term investors willing to accept corporate credit risk, SPLB is recommended as the better buy due to lower costs and superior income generation.